Background and Objective: Alterations in the grey matter volume of several
| INTRODUCTION
Emerging evidence from modern brain imaging investigations identifies a strong association between chronic pain and a decrease in grey matter volume (Cauda et al., 2014; May, 2008; Yuan et al., 2017) . While these findings have been reported for a range of brain structures (e.g., thalamus, insular cortex), meta-analyses (Cauda et al., 2014; Lin, Lee & Weng, 2016; Shi, Yuan, Dai, Ma & Sheng, 2016) have consistently demonstrated decreased grey matter volume in the medial prefrontal cortex (mPFC) across various chronic pain conditions (e.g., nociceptive, neuropathic, inflammatory). The mPFC is critically involved in numerous cognitive functions such as decision making (Bechara & Damasio, 2005) , executive control (Posner, Rothbart, Sheese & Tang, 2007) , conflict monitoring (Botvinick, Cohen & Carter, 2004) , error detection (Holroyd, Coles & Nieuwenhuis, 2002) , learning (Rushworth, Noonan, Boorman, Walton & Behrens, 2011) and memory (Frankland, Bontempi, Talton, Kaczmarek & Silva, 2004) . The mPFC is also of particular interest when considering emotional processing in the brain (Etkin, Egner & Kalisch, 2011) . It is well known that chronic pain is commonly comorbid with affective disorders such as anxiety and depression (McWilliams, Cox & Enns, 2003; Tsang et al., 2008) , with comorbid prevalence ranging up to 54% for depression (Campbell, Clauw & Keefe, 2003) and up to 35% for anxiety (McWilliams et al., 2003) . Structural changes within the mPFC have been shown to be associated with changes in emotionality in people with chronic pain (Gustin, McKay, et al., 2014) . Given the consistent observations of decreased grey matter density in the mPFC and their association with cognitive functions, emotionality and affective disorders in patients with chronic pain, a detailed understanding of the pathophysiology of the mPFC is important. However, there is a gap in the literature on the biochemical and cellular mechanisms that underpin these grey matter changes in the mPFC of people with chronic pain.
In the brain, an observation of decreased grey matter volume (primarily consisting of neuronal cell bodies, glia and other neuropils) (Purves et al., 2004 ) is commonly thought to be associated with neuronal loss. This process is not only seen in age-related changes in the normal human brain (Ge et al., 2002; Pakkenberg & Gundersen, 1997) , but also widely recognised in neurodegenerative diseases such as dementia. For example, hippocampal (grey matter) atrophy identified using both ante-and postmortem magnetic resonance imaging (MRI) in dementia have been validated by postmortem histopathological examination to reflect primarily neuronal loss (Bobinski et al., 1999; Jack et al., 2002) . However, in the context of chronic pain, evidence from multimodal brain imaging techniques points away from neuronal loss as the likely explanation for mPFC grey matter decrease (Pomares et al., 2017) . Instead, recent evidence has suggested alternative causes. For example, changes in neuronal morphology, such as the shape and size of dendritic spines (Kuner, 2010; Metz, Yau, Centeno, Apkarian & Martina, 2009) , are a form of structural plasticity that may present as a decrease in grey matter. Furthermore, a dysregulation in metabolic activity may also contribute to alterations that present as decreased grey matter. For example, in people with chronic pain, a decrease in grey matter is associated with reduced γ-Aminobutyric acid (GABA) (Henderson et al., 2013) , which can affect vascular networks (Attwell et al., 2010) , that appear as decreases in grey matter on T1-weighted imaging (Franklin et al., 2013) .
In summary, it is unclear what a reduction in mPFC grey matter represents in the brain in the context of chronic pain. This is important to understand because the common perception of grey matter decrease in the mPFC to reflect neuronal loss, although logical, might be misleading. Therefore, the purpose of this article is to evaluate and discuss the existing literature to unravel what the decrease in grey matter in the mPFC of people with chronic pain may represent.
| WHAT WE KNOW SO FAR ABOUT MPFC CHANGES IN CHRONIC PAIN
While evidence suggests that grey matter volume decreases are present in the mPFC in people with chronic pain, the biochemical and cellular underpinnings remain unclear. To date, there are no studies that provide histologic evidence of medial prefrontal atrophy in humans with chronic pain. Several longitudinal voxel-based morphometric studies have demonstrated reversibility of grey matter volume after successful management and elimination of chronic pain in the amygdala, thalamus, brainstem, anterior cingulate cortex (ACC), dorsolateral PFC and insular cortex (Gwilym, Filippini, Douaud, Carr & Tracey, 2010; Obermann et al., 2009; Rodriguez-Raecke, Niemeier, Ihle, Ruether & May, 2009; Seminowicz et al., 2011) . Given that neurodegeneration is irreversible (May, 2009) , this suggests that grey matter decrease is not due to neuronal death but rather other alterations in neuronal tissue. This is supported by studies of magnetic resonance spectroscopy markers of neuronal integrity in fibromyalgia patients which confirm that grey matter decreases were not due to compromised neuronal viability (Pomares et al., 2017) . Although neurodegeneration has been observed in the human spinal cord in the peripheral nerve injury model of neuropathic pain (Watson, Deck, Morshead, Van der Kooy & Evans, 1991; Zimmermann, 2001) , there is no direct evidence that this pattern is evident in higher-order supraspinal structures, including the mPFC (Schmidt-Wilcke, 2008; Seminowicz et al., 2009 ). Animal models are currently at the frontier of research in unravelling the cellular and molecular causes of grey matter changes in the mPFC. Notably, animal models of chronic pain that have focussed on morphological and functional changes in the mPFC did not show evidence of neuronal loss as a potential cause of grey matter decrease (Metz et al., 2009 ).
In the light of these findings, alternative pathways and causes have been explored in an effort to describe the nature of grey matter changes. In animal models, both spared nerve injury and chronic stress models have been utilised for chronic pain research. Spared nerve injury models mimic acute peripheral injuries leading to chronic pain states, while chronic stress models simulate the plastic changes in sustained stress responses observed in chronic pain (VachonPresseau, 2017; Vachon-Presseau et al., 2013) and are based on the diathesis-stress model of chronic pain (Turk, 2002) . Results of these studies show that in rodent models, changes in the morphology of dendrites have been shown to influence grey matter volume. This includes decreased apical dendritic length, volume, and branching in layer 5 and 2/3 pyramidal neurons in the mPFC which have been found in both the spared nerve injury and the chronic stress rat models (Cook & Wellman, 2004; Kelly, Huang, Meltzer & Martina, 2016; Radley et al., 2004 Radley et al., , 2006 Radley et al., , 2008 . Although Metz et al. (Metz et al., 2009 ) report increased length and arbour in the basal dendrites of layer 2/3 pyramidal cells in the mPFC, this significant alteration in morphology nevertheless may still contribute to changes in grey matter. Interestingly, dendritic morphology has been suggested to be one of the main factors that can influence grey matter volume observed in human neuroimaging (Zatorre, Fields & Johansen-Berg, 2012) .
Furthermore, a significant portion of alterations in dendritic morphology may be a result of multifaceted pathways as a result of chronic stress in chronic pain. For example, regulatory stress hormones such as elevated cortisol found in people with chronic pain (Vachon-Presseau, 2017; VachonPresseau et al., 2013) may impact dendritic reshaping, such as the development of dendritic trees (Bitzer-Quintero & González-Burgos, 2012; Erickson, Drevets & Schulkin, 2003) . Similarly, the release of immune mediators associated with neuroinflammation (Fiore & Austin, 2016) in chronic pain, such as cytokines, has also been suggested to alter the morphology of dendritic spines (Bitzer-Quintero & Gonzá-lez-Burgos, 2012; Costigan et al., 2009; Vachon-Presseau et al., 2013; Yang, Parkhurst, Hayes & Gan, 2013) .
Neurotransmitter systems must also be considered as they have been consistently shown to be dysregulated in the mPFC in chronic pain. Various animal models of neuropathic pain have shown either significant increases (Fiore & Austin, 2016; Hung, Wang, Wang, Chiang & Wang, 2014; Metz et al., 2009; Xu et al., 2008) or decreases (Guida et al., 2015; Kelly et al., 2016; Palazzo et al., 2016) in glutamate levels in this region. It has been suggested that, following injury, there is an initial increase in glutamate during the acute phase that is followed by a decrease during its progression to chronicity (Guida et al., 2015) . Decreases in GABA have been found in the rat ACC (Narita et al., 2011; Yamashita et al., 2014) , which is a subregion of the mPFC in the rodent model (Öngür & Price, 2000) . While the causal links between these neurotransmitter levels and grey matter volume are yet to be identified, evidence is growing to suggest an association between glutamate and GABA in the mPFC of chronic pain patients. For instance, processes such as astrocyte morphology (Fiore & Austin, 2016) or dendritic spine count (Metz et al., 2009 ) may also have modulatory roles in the levels of glutamate and GABA, and vice versa (Herman, Mueller & Figueiredo, 2004) .
Perfusion and vasculature are extracellular factors that have been proposed to contribute to grey matter decreases (Newman, Moulton, Becerra & Borsook, 2014; SchmidtWilcke, 2008) . Changes in the local microvascular network (e.g. capillaries) can masquerade as reduced grey matter volume on magnetic resonance imaging (Franklin et al., 2013; Schmidt-Wilcke, 2008) . Using positron emission tomography, decreased cerebral blood flow in the mPFC has been observed in people with chronic pain (Honda, Maruta & Takahashi, 2007) . However, the opposite has been found in the animal model of chronic pain-an increase in neuronal activity and, thus, increased perfusion has been detected in the rat ACC (Blom, Pfister, Santello, Senn & Nevian, 2014; Wei & Zhuo, 2001) .
Given the plethora of potential cellular underpinnings of mPFC grey matter changes in chronic pain, we have utilised a model-based approach in the following section in order to elucidate the available evidence and propose both preceding and concurrent factors in the pathophysiology of chronic pain.
| BRINGING THE EVIDENCE TOGETHER-A MODEL-BASED APPROACH
In general, there are gaps in the literature regarding the histological underpinnings of mPFC grey matter changes in chronic pain. Current evidence suggests that the decrease in grey matter detected in the mPFC of people with chronic pain is likely due to causes other than cell death and neurodegeneration. We propose a model ( Figure 1 , Table 1 ) in which two major pathophysiological pathways lead to two distinct alterations in the grey matter of the mPFCnamely dendrite morphology and neurotransmitter content. This model stems from a stress model of chronic pain, wherein maladaptive physiological responses play critical roles in the development and maintenance of chronic pain. We developed our model reviewing mPFC alterations in structure, function and biochemistry in both the animal and the human literature of chronic pain. It is important to note there is a discrepancy between the length of ongoing pain in animal models compared to human studies of chronic pain. In humans, chronic pain is usually defined as persisting beyond the normal healing time of about three to six months (Merskey & Bogduk, 1994) . In animal studies, there is a variance of from three to thirty days of ongoing pain. Therefore, our model should not be used to present a state of pain, for example, acute vs. chronic, nor the transition from an acute to a chronic state, but rather to reveal the underlying biochemical and cellular mechanisms of mPFC grey matter alterations.
| Dendrite morphology and stress
Changes in dendrite morphology, mostly expressed by decreases in volume and arbourisation, have been observed in the rodent model of both chronic pain and stress (Cook & Wellman, 2004; Kelly et al., 2016; Radley et al., 2004 Radley et al., , 2006 Radley et al., , 2008 . While these observations have only briefly been reported in humans (Blix, Perski, Berglund & Savic, 2013; Frodl, Reinhold, Koutsouleris, Reiser & Meisenzahl, 2010) , they have been proposed as the basis for the grey matter volume changes detected by magnetic resonance imaging (Golub et al., 2011; Kassem et al., 2013; Lee, Jarome, Li, Kim & Helmstetter, 2009; Zatorre et al., 2012) . Our model for grey matter volume changes in chronic pain ( Figure 1 ) proposes an analogous model to that described in Kassem et al. (2013) -that the primary cause for the change in grey mater volume in the mPFC is caused by a change in dendritic morphology. Indeed, given the biopsychosocial nature of chronic pain (Abdallah & Geha, 2017; Blackburn-Munro & Blackburn-Munro, 2001; Sternbach, 1986; Vachon-Presseau et al., 2013) , a dysregulated stress response likely contributes to its pathogenesis. Particularly as the mPFC is especially vulnerable to the effects of stress (Goldwater et al., 2009; Holmes & Wellman, 2009; PerezCruz, Muller-Keuker, Heilbronner, Fuchs & Flugge, 2007; Schweinhardt & Bushnell, 2010) .
The process behind grey matter volume loss in chronic stress, and as we argue chronic pain, is summarised in Figure 2. This sharing of a similar process is supported by a parallel use of the hypothalamo-pituitary-adrenal (HPA) axis. The HPA axis is responsible for the body's adaptive response to stress, and it is known that chronic pain is associated with HPA axis dysfunction (Bomholt, Harbuz, Blackburn-Munro & Blackburn-Munro, 2004; Hannibal & Bishop, 2014; Ulrich-Lai et al., 2006) as they share common neuroendocrine responses (Blackburn-Munro & Blackburn-Munro, 2001 ). Our primary interests are glucocorticoids (commonly called cortisol) and corticosteronereleasing hormone (CRH), the main hormonal products of the HPA axis, which have been repeatedly reported to have a role in altering dendritic morphology (Bennett, 2011; Bennett, Farnell & Gibson, 2010; Bitzer-Quintero & González-Burgos, 2012; Erickson et al., 2003; Kassem et al., 2013; Wellman, 2001 ). Glucocorticoids and CRH levels are normally elevated in the body's adaptive response to acute stress (i.e., a one-off event), they can be measured as indicators of the pain-stress cycle and have been proposed to parallel the development of chronic pain (Gatchel, 2004; Melzack, 1999) .
Examining this parallel closer, we indeed see abnormally elevated levels of glucocorticoids in people with chronic pain (Catley, Kaell, Kirschbaum & Stone, 2000; McBeth et al., 2005; Patacchioli et al., 2006; Peres et al., 2001; Vachon-Presseau et al., 2013; Van Uum et al., 2008) . But further, we see a shared yet slightly different dysfunction of the HPA axis between chronic stress and chronic pain, as not only is there hypercortisolism (overabundance of glucocorticoids) but also evidence of hypocortisolism (underabundance of glucocorticoids) in people with chronic pain (Buryanov, Kostrub & Kotiuk, 2017; Muhtz et al., 2013; Riva, Mork, Westgaard, Rø & Lundberg, 2010) . What this illustrates is an overarching theme of HPA axis dysfunction as a major factor in chronic pain pathology. We believe that this congruence to chronic stress justifies the use of a chronic stress-like model of grey mater volume loss to explain the changes in grey matter volume seen in chronic pain-ultimately as the influx of glucocorticoids and CRH, the collapse of synaptic spines, the retraction of dendrites and then the loss of grey matter volume.
The stress mechanisms resulting from HPA axis dysfunction explain the reduced dendritic volume seen in the mPFC of animal models of chronic pain (Kelly et al., 2016) (Figure 1 ). This same mechanism we argue is F I G U R E 2 Illustrative flow chart detailing the loss of grey matter volume via the loss of synaptic spines caused by chronic stress. The figure is divided into the three stages of grey matter volume loss, HPA axis dysfunction (blue), dendritic morphology (red), loss of grey matter (grey). The black squares in the figure represent glucocorticoid (stripped) and CRH (solid), while the objects that are white with black outline represent receptors (strippedglucocorticoid, solid-CRH, "C" shaped-NMDA). Following the figure, we start with a healthy synaptic spine that when subjected to stress, is exposed to increased glucocorticoids and CRH, causing a loss of calcium ion influx, leading to the collapse of the spine, retraction of the dendrite, and ultimately loss of grey matter volume. HPA = hypothalamo-pituitary-adrenal, CRH = corticosterone-releasing hormone, NMDA = N-methyl-D-aspartic acid occurring in the human mPFC in chronic pain, which may be the underlying reason for decreased grey matter volume detected by magnetic resonance imaging (Cauda et al., 2014; Lin et al., 2016; Shi et al., 2016) (Figure 1) . However, there is currently a lack of human studies, postmortem or otherwise, which examine mPFC neuronal morphology in humans, and this caveat, as we argue, demands further attention.
| Neurotransmitter dysregulation
Non-neuronal glial cells undergo structural and functional alterations in the central nervous system in chronic pain (Milligan & Watkins, 2009) . While a description of the complex interplay between glia and neurons is beyond the scope of this review, it should be noted that astrocytes and microglia (collectively referred to as glia) have critical roles in pain processing-such as modulating the balance between glutamate and GABA (Gosselin, Suter, Ji & Decosterd, 2010; Gwak & Hulsebosch, 2011; Milligan & Watkins, 2009) . In chronic pain, these cells undergo various processes and become known as "activated" glial cells. Indeed, glial activation has been shown in the human brain in chronic pain (Loggia et al., 2015) and in the animal ACC in inflammatory pain (Chen et al., 2012; Ikeda, Mochizuki & Murase, 2013) . This has also been well demonstrated in spinal cord neurons in animal models of chronic pain (Ji, Berta & Nedergaard, 2013; Tsuda et al., 2003) . Interestingly, Alshikho and colleagues recently revealed that increased Glia activation, measured by [
11 C]-PBR28 PET, colocalizes with alterations in grey matter volume (Alshikho et al., 2018) . Glial activation leads to the production of signalling pathways such as cytokines (e.g., TNFa, IL-1B) which downregulate neurotransmitter transporter function (i.e., GABA & glutamate) (Milligan & Watkins, 2009 ). Further to this argument, Gosselin et al. (2010) described in detail pathways for microglial and astrocytic events in the spinal cord in neuropathic pain, in which via activation of p38 MAPK and intracellular JNK pathways, respectively, result in concomitant processes that reinforce pain signalling through altering GABA and glutamate uptake (Figure 3 ). It has been suggested that such uptake mechanisms modulated by neurons and glial cells control extracellular glutamate and GABA concentrations (e.g., in the synaptic cleft) (Gosselin et al., 2010; Gwak & Hulsebosch, 2011) . Indeed, a dysregulation of glutamate and GABA, the brain's main excitatory and inhibitory neurotransmitters, respectively, has been observed in various brain regions of people with chronic pain (As-Sanie et al., 2016; Gustin, Wrigley, et al., 2014; Henderson et al., 2013) . This same phenomenon has been demonstrated in the mPFC of animal models (Fiore & Austin, 2016; Guida et al., 2015; Hung et al., 2014; Kelly et al., 2016; Metz et al., 2009; Narita et al., 2011; Palazzo et al., 2016; Toyoda, Zhao & Zhuo, 2009; Xu et al., 2008; Yamashita et al., 2014) . Interestingly, Harris and colleagues revealed a significant increase in posterior insula glutamate levels but no alterations in N-acetylaspartate (NAA) in people with fibromyalgia (Harris et al., 2009) . As NAA is a marker of neuronal variability (Rae, 2014) , for example, neuronal loss, a lack in NAA alteration suggests that the change in glutamate is not due to neuronal loss rather than Glia activation. Collectively, we argue that these changes in neurotransmitter levels (GABA & glutamate) regulate blood flow and hence vascular change (Figure 4 ). Glutamatergic and GABAergic decreases are critical when considering the causes of grey matter decreases because they can lead to vascular changes (Attwell et al., 2010) that have been proposed to appear as grey matter decreases on T1-weighted scans (Franklin et al., 2013; Schmidt-Wilcke, 2008) . For example, glutamate and GABA have been observed to influence microvasculature through neurovascular signalling and activation of pericytes-contractile cells that line capillaries, controlling their diameter size through contraction or dilation (Figure 4) (Attwell et al., 2010) . This altered capillary size (Kuschinsky & Paulson, 1991) can result in changes in blood flow or volume in various brain regions, including the mPFC (Honda et al., 2007) , in people with chronic pain (Di Piero et al., 1991; Hsieh, Belfrage, Stone-Elander, Hansson & Ingvar, 1995; Kwiatek et al., 2000; Nakabeppu et al., 2001 ). The idea that decreased blood flow results in decreased grey matter has been corroborated by T1-weighted and arterial spinlabelled imaging. For example, Franklin et al. (2013) scanned subjects pre-and postsingle a dose of baclofen (a GABA analogue) to induce changes in cerebral blood flow. They revealed a significant overlap between regions of decreased cerebral blood flow and grey matter volume ( Figure 5 ). Therefore, this association suggests that dysregulation of neurotransmitter-mediated blood flow may be masquerading as the grey matter decreases we see in the mPFC of people with chronic pain.
It is important to acknowledge that there is a potential interplay between the pathways in our model (Figure 1 ). Glia and cytokine expression are also involved in the regulation of dendritic morphology (Bitzer-Quintero & Gonzá-lez-Burgos, 2012) which in turn can affect mPFC grey matter volume if we reference our previous argument. On the other hand, the potential relationship between neurotransmitter dysregulation and HPA axis dysfunction remains to be explored. For example, it is known that glutamate affects the HPA stress response-specifically, glutamate regulates adrenocorticotropic hormone release which, in turn, affects the synthesis of cortisol (Herman et al., 2004) . Additionally, glutamate has been shown to be dysregulated in both acute stress (Popoli, Yan, McEwen & Sanacora, 2012 ) and early stages of pain (Guida et al.,
T A B L E 1 Overview of studies in HPA axis dysfunction, altered dendrite morphology, glial activation, and neurotransmitter dysregulation in chronic pain/stress. Abbreviations: anterior cingulate cortex (ACC), γ-Aminobutyric acid (GABA), GABA transporter (GAT), glial fibrillary acidic protein (GFAP), medial prefrontal cortex (mPFC), spared nerve injury (SNI), HPA (hypothalamic-pituitary-adrenal)
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Model type Observed changes HPA axis dysfunction . There may be a concurrent effect on cortisol and dendritic morphology that is yet to be understood in the context of chronic pain. Hence, the gravity of the interactions between the two pathways in our model (Figure 1 ) must not be dismissed when considering an explanation for the understudied changes seen in mPFC grey matter volume in chronic pain. As a final point, the biochemical and cellular ramifications of our model of grey matter volume loss in the mPFC demonstrate disruption of mPFC function-a dysfunction proposed to reduce descending pain-inhibitory signals with a relative unleashing of ascending noxious input, resulting in increased persistent pain and limiting the ability to react adaptively to ascending pain signals (Garcia-Larrea & Peyron, 2013). Indeed, a recent study in the mouse model of chronic pain showed that chronic restriction injury induced (a) maladaptive excitatory and inhibitory circuit pathways of mPFC neurons connected to the descending analgesic network and (b) triggered an imbalance in inhibitory and excitatory input to mPFC neurons which directly ascend from the periaqueductal grey (Cheriyan & Sheets, 2018) .
| AVENUES FOR FUTURE RESEARCH
Histological examination of the mPFC in people with chronic pain would provide powerful evidence for the , including investigating the validity of dendrites as a major cause and excluding the role, or lack thereof, of neurodegeneration for decreased mPFC grey matter. However, to date, this
has not yet been performed-possibly due to associated practical difficulties. Furthermore, glial count should also be measured given the role of glial activation in chronic pain states. Although levels of glutamate and GABA have never been measured in the mPFC of people with chronic pain, emerging evidence has revealed glutamatergic/ GABAergic dysregulation in the animal mPFC and in other brain regions of human models. For example, a recent systematic review of spectroscopy studies in migraine cohorts revealed glutamate and GABA dysfunction consistent with our model of imbalanced excitatory and inhibitory activity in the cerebellar, cingulate, occipital and parietal cortices (Younis, Hougaard, Vestergaard, Larsson & Ashina, 2017) . This supports a cortical hyperexcitability hypothesis of chronic pain that is underpinned by glutamatergic/GABAergic imbalance (Zielman et al., 2017) . Given these findings in other regions, directly measuring neurotransmitter alterations in the human mPFC would support our hypothesis of a dysregulated glutamatergic excitation/GABAergic inhibition balance in chronic pain. An astrocytic activation also occurs (characterized by an activation of the intracellular JNK pathway) consequently to both neuronal releases of high amounts of neuromediators and microglial production of cytokines such as TNF-α. As a result of astrocyte reaction, a reduction in glutamate scavenging capacity together with an increase in GABA uptake reinforces pain signalling as well. Furthermore, reactive astrocyte release cytokines such as CCL2, participating in the loss of the GABAergic inhibition (copied with permission from Gosselin et al., 2010, Neuroscientist) A novel technique for examining GABA levels would be the GABA-edited MEGA-PRESS spectroscopy (Edden & Barker, 2007) . Single voxel proton magnetic spectroscopy is an established technique to measure glutamate levels (Schubert, Gallinat, Seifert & Rinneberg, 2004) . Notably, some therapeutics modulate GABA/glutamate release and receptor activity, for example, cannabinoids (Rea, Roche & Finn, 2007) , anticonvulsants (Baidya, Agarwal, Khanna & Arora, 2011) , N-methyl-D-aspartate receptor antagonists (Sleigh, Harvey, Voss & Denny, 2014) , benzodiazepines (Fischer, 2017) and antispasmodics (Franklin et al., 2011) . As changes in GABA and glutamate levels result in alterations in resting state cerebral blood flow (Franklin et al., 2013) , which in turn appear as alterations in grey matter volume in MRI (Attwell et al., 2010) , any of these therapeutics should be considered when we discuss alterations in mPFC grey matter volume. Indeed, there is growing evidence that opioid exposure alters cortical and subcortical grey matter volume (Upadhyay et al., 2010; Younger et al., 2011) possibly through effects on modulated GABA A receptor functioning (Zarrindast et al., 2004) , modified glutamate receptor targeting (Glass, Kruzich, Colago, Kreek & Pickel, 2005) and/or activation on HPA axis (Bryant, Bernton, Kenner & Holaday, 1991; Kreek, 1996; Pechnick, 1993) . Critically, morphine-induced grey matter volume changes may not reverse after opioid cessation. The chronicity of these alterations may be mediated by plastic changes in the central nervous ] i may also (dashed line) generate arachidonic acid (AA) from phospholipase A 2 (PLA 2 ), which is converted by COX2 to prostaglandins (PG) that dilate vessels. Glutamate raises [Ca 2+ ] i in astrocytes by activating metabotropic glutamate receptors (mGluR), generating arachidonic acid and thus three types of metabolite: prostaglandins (by COX1/3, and COX2 in pathological situations) and EETs (by P450 epoxygenase) in astrocytes, which dilate vessels, and 20-HETE (by ω-hydroxylase) in smooth muscle, which constricts vessels. A rise of [Ca 2+ ] i in astrocyte endfeet may activate Ca 2+ -gated K + channels (g K(Ca) ), releasing K + , which also dilates vessels (copied with permission from Attwell et al., 2010; Nature) . It should be noted that this figure is currently outlining glutamate-mediated control of arteriole smooth muscle. However, it is assumed that the signalling pathways controlling pericyte constriction and dilation will be similar to those for arterioles in this figure (Attwell et al., 2010) . Although GABA is not included in this figure, it maintains a critical role in mediating a component of vasodilation in the cortex (Attwell et al., 2010) system, for example alterations in GABA/glutamate release and receptor activity, induced by adverse opioid effects, for example dependency (Younger et al., 2011) . Furthermore, depending on the type of chronic pain condition, the extent of changes may vary for either of our proposed causes of decreased mPFC grey matter volume (Figure 1) . Indeed, it is unclear which pathway is more prominent in which condition. For example, despite lower back pain and fibromyalgia both being associated with decreased mPFC grey matter, both demonstrate different levels of cortisol (Fritz et al., 2016; Griep et al., 1998; Shi et al., 2016) . This suggests that the decreased mPFC grey matter volume may be more heavily influenced from one particular pathway than another, for example, more so dendrite morphology than neurotransmitter dysregulation. However, the fact that decreased mPFC grey matter volume is prominent across varying types of pain, such as neuropathic, nociceptive and inflammatory (Cauda et al., 2014; Lin et al., 2016; Shi et al., 2016) , suggests that these two changes are common phenomena within chronic pain as a whole. Future studies should measure markers in both pathways in chronic pain cohorts in order to compare and evaluate which pathophysiological mechanism in the mPFC is more prominent. When translating our model into clinical significance, it is also critical to identify the predominant pathological pathway as a stepping stone towards novel chronic pain treatments. For example, there are mixed findings of the relationship between decreases in mPFC grey matter volume and affective disorders such as anxiety and depression in people with chronic pain. While some articles demonstrate a negative correlation between mPFC grey matter volume with anxiety and depression (Diaz-Piedra, Guzman, Buela-Casal & Catena, 2016; Seminowicz et al., 2010) , others reveal no significant relationship (Abdallah & Geha, 2017; Ivo et al., 2013; Mansour et al., 2017; Robinson, Craggs, Price, Perlstein & Staud, 2011) . The reason for this difference may be dependent on the major pathological pathway in our model, which may inevitably vary according to the type and/or severity of the chronic pain condition, and/or the type of the comorbid affective symptoms. Notably, Glu mediates the behavioural sequelae associated with anxiety and stress (Cortese & Phan, 2005) . Major depression is associated with a decrease in mPFC GABA tone, induced by a dysfunction of mPFC GABA release and uptake secondary to chronic stress . Interestingly, a decrease in mPFC grey matter volume is not only revealed in people with chronic pain (Cauda et al., 2014) but also revealed in people with major depressive and anxiety disorders (Huey et al., 2015; Koolschijn et al., 2009) . Furthermore, both cumulative and recent stressful life events are both associated with reduced mPFC grey matter volume (Ansell, Rando, Tuit, Guarnaccia & Sinha, 2012) . Indeed, stress can alter mPFC dendritic morphology in a relatively short period of time (Brown, Henning & Wellman, 2005) . Given these striking similarities, the overarching role of chronic stress in the multifaceted biopsychosocial nature of chronic pain (including depression and anxiety) may be the essential precursor to both pathways of HPA axis dysfunction and neurotransmitter dysregulation (Figure 1) that ultimately masquerades as reductions in mPFC grey matter volume. Additionally, a smaller mPFC volume may increase the risk of developing stress-related disorders (Ansell et al., 2012 )-a vicious cycle that predisposes individuals to the development and maintenance of chronic pain. Given their relevance and association with chronic pain, the pathophysiological roles of both chronic stress and affective disorders should be further explored in future studies in order to understand the multifactorial nature of chronic pain.
Another consideration is the role of sex differences on the stress model of chronic pain. As the vast majority of animal studies in this review have exclusively used male rodents, it is difficult for our model to account for sex differences. Sexual dimorphism has been known to influence the generation and presentation of chronic pain, in particular in the stress model of chronic pain. For example, in the animal model of neuropathic pain, it has been shown that how early life stress impacts neuronal activity in the mPFC varies between males and females (Nishinaka, Nakamoto & Baclofan-induced regional decreases in cerebral blood flow (CBF) and decreases in grey matter volume. Considerable overlap between grey matter volume and CBF findings was observed in subregions of both the posterior and anterior cortices and several other brain regions. Red = perfusion differences, blue = grey matter differences and purple = regions of overlap (copied with permission from Franklin et al., 2013, Brain Structure Function) Tokuyama, 2016). Therefore, future studies should consider the impact of sexual dimorphism on the biochemical and cellular mechanisms that underpin mPFC grey matter changes in chronic pain.
Finally, it is also important to acknowledge that our proposed causal model of mPFC grey matter only reflects patterns in the mPFC. There are meta-analyses showing alterations in other brain structures such as the insula (Cauda et al., 2014) or the sensorimotor cortex (Cauda et al., 2014) , which are less sensitive to stress hormones than the mPFC. Therefore, our proposed model cannot account for the grey matter loss in other brain regions.
| CONCLUSION
This review has identified the gaps in the literature for cellular and biochemical causes for the decrease in grey matter seen in the mPFC of humans. We have suggested dendrite morphology and neurotransmitter dysregulation as the two major factors that could contribute to the apparent decrease in grey matter seen in the mPFC of people with chronic pain. It is possible that there is a complex interplay between the two mechanisms in the pathophysiology of chronic pain.
